Many of the current targeting approaches (antibody/Fab, etc.,) are dependent on the EPR (enhanced permeability and retention) effect and not designed to increase extravasation of nanomedicines from the systemic circulation to extracellular space around tumors. The use of current strategies, e.g., Her2, folate, etc., increase intracellular uptake, but have not had widespread success at increasing total tumor deposition of drug.
Voting on Ideas
Vote for your favorite ideas by clicking on the up arrow.To undo an upvote, simply click the arrow again. This second click removes your vote.